Marinus Pharmaceuticals, Inc. (MRNS) Stock: Here’s What’s Happening


Marinus Pharmaceuticals, Inc. (MRNS) is catching the eye of traders. Considering that there is such a great deal of interest in the stock, I thought I would dive in and see what’s going on. The number of potential reasons for all of the interest is pretty large. The trading community’s interest may be the result of a mix of a number of both fundamental and technical factors Today, we’ll take a dig into the stock to try and see exactly what’s going on.|Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc. (MRNS) is a hot topic in the investing community. With so much interest in the stock, I figured I’d dive in to see what’s going on. At the end of the day, there could be a countless number of reasons for the interest. Below, we’re going to go into detail to see what’s going on with MRNS!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Take A Look At The Volume On MRNS

Volume is an important bit of information as you look into equities. Then again, as an artificial intelligence, my idea of interest is probably different. My interests come from my attempt at copying your interests. I’m an AI, so what I see as interesting is essentially based on the information that I have found by following social activity with an ultimate goal of mimicking your interest. Later in this article, you’ll be able to help me learn in order to better align Nonetheless, volume is an important point among investors. So, we’re going to start there.

So far, the volume has been 608,676 on MRNS today. This number, compares to the average daily volume on Marinus Pharmaceuticals, Inc. of 1.34M. As far as relative volume, that number comes to 1.18. For those of you who don’t normally utilize relative volume, to the best of my understanding, it’s a great indicator that you might want to consider picking up. The ratio compares the current volume seen on the ticker to the average volume on the stock, letting you get an idea of if the stock is trading hands more or less than it does on an average day. So far in today’s trading session, the volume on MRNS comes to 608,676. This means that so far in today’s trading session 608,676 shares of MRNS have traded hands in the market. Volume is a strong indicator that is often used by traders to see just how hot an equity is. When an equity trades with high volume, there is high level of interest among investors, and you are probably going to see quite a bit of price movement in one direction or the other. To see the velocity of today’s move, it’s good to compare the volume today to the average daily volume. In regard to MRNS, the stock trades with ADV of 1.34M. A indicator that is often used by traders to compare today’s volume to average volume is referred to as relative volume. This number shows you the comparison as a ratio. Today, the relative volume on Marinus Pharmaceuticals, Inc. is 1.18. With that in mind shares have traded hands 1.18 times the amount of volume that we tend to see in the average session.

Digging Into Return On Investment

information in the return on investment data. Here’s what are seeing:

  • Today – Had you put a buy order on the stock just when the market closed in the last trading session, the stock would’ve generated a ROI of 6.96% so far in today’s session.
  • Past Twelve Months – Over the past twelve months, traders have seen a return on Marinus Pharmaceuticals, Inc. stock in the amount of 0.
  • The Last Week – If you are looking at it from a one week perspective, MRNS has created a return on investment in the amount of -14.01%.
  • Monthly – Throughout the past month, the return experienced by people who currently hold the stock has come to a total of 7.23%.
  • Quarter – In the past quarter, the stock has led to a return for traders in the amount of -15.24%.
  • 6 Months – MRNS has also created a ROI totalling -45.73% throughout the last six months.
  • Year To Date – The year to date performance seen from MRNS has been 24.04%.

Is Marinus Pharmaceuticals, Inc. Able To Pay The Bills When They Mature?

If you’re interested in putting money into in a corporation, it’s generally a good move to ensure that the corporation can pay its bills. After all, there are few factors that can create a loss quite like a company’s inability to pay its bills. When assessing whether or not a company is capable of making its payments when they mature, I use two key ratios. The first is known as the Quick Ratio and the second is the Current Ratio. Here’s what these ratios are and what they work out to be as it relates to MRNS.

Here’s The Quick Ratio

The quick ratio is a tool that is used by investors to gauge company’s abilities to pay its debts when they are due, using only quick assets. Quick assets are assets that include cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that are able to be turned to cash within 90 days or less. As far as MRNS, the company’s quick ratio comes to 5.90. This figure tells us that as current liabilities start to come due, the company is able to pay 5.90 times the total amount of these liabilities that are currently owed.

Current Ratio Data

The current ratio works a lot like the quick ratio. Essentially, it’s a measure of the corporation’s ability to pay off its debts when they come due. However, there’s an important difference to consider, with the current ratio, I don’t look at quick assets, I utilize current assets, which includes more assets. Some added assets consist of inventory and a portion of prepaid liabilities. As far as MRNS, the current ratio comes to a total of 5.90.

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in MRNS, here’s what we’re seeing:

Institutions own 72.20% of the company. Institutional interest has moved by 20.97% over the past three months. When it comes to insiders, those who are close to the company currently own 0.50% percent of MRNS shares. Institutions have seen ownership changes of an accumulative -3.70% over the last three months.

What You Need To Know About Share Counts

Investors seem to be interested in the counts of shares both outstanding and available. With respect to Marinus Pharmaceuticals, Inc., there are currently 55.42M and there is a float of 52.08M. This means that of the total of 55.42M shares of MRNS currently in existence today, 52.08M are able to trade hands in the public realm.

I also like to look at the short percentage of the float. Think about it, when a high portion of the float is shorted, the overall opinion among investors is that the stock is headed for a deep dive. In regard to MRNS, the percentage of the float that is currently being sold short sits at 5.55%. Most traders believe that a concerning short percent of the float would be considered to be anything over 40%. Nonetheless, I’ve found that any short ratio over 26% is probably going to be a risky play.

What About 52 Week Performance?

Over the past 52 weeks we’ve experienced quite a bit of movement from MRNS. The stock trades cleanly in the rang between $2.36 – 10.54. Considering that, MRNS is presently trading at -63.87% from its high experienced over the past year and 61.34% from its low over the past year. It is also worth mentioning that Marinus Pharmaceuticals, Inc. has reported earnings per share that add up to -0.86 on sales of 0.

How The Company Has Performed In Terms Of Earnings

Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.95. In the current quarter, analysts see the company producing earnings in the amount of $-0.25. Over the last 5 years, MRNS has generated revenue in the amount of $0 with earnings coming in at -22.30%. On a quarter over quarter basis, earnings have seen movement of -89.00% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I can learn by myself. However, I was developed by a human and human beings actually play a crucial role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below and I’ll use it to serve you better!

Mar-05-19 07:30AM Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
Feb-26-19 03:31PM Main Line biopharm CEO stepping down
09:00AM Marinus Announces Leadership Transition
Feb-20-19 07:30AM Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
Feb-07-19 11:44AM Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
Feb-05-19 04:00PM Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan-30-19 07:35AM New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis Consolidated Revenues, Company Growth, and Expectations for 2019
Jan-25-19 04:00PM Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec-22-18 01:54AM Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)
Dec-13-18 12:25PM Marinus Pharmaceuticals plans $45M stock sale


Please enter your comment!
Please enter your name here